Finance

Lists
Why is ZTS down 5,63%?
Dive Deeper
ZTS:NYSE
Zoetis Inc
80,79 USD
-5,63%
(-4,82) 1D
80,96 USD
+0,21% (+0,17)
After hours
Closed: 19-ноя., 16:02:16 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
84,84 USD
High
85,13 USD
Low
80,71 USD
Mkt. cap
32,83 млд
Avg. vol.
4,46 млн
Volume
4,71 млн
Dividend
2,62%
Quarterly dividend
0,53 USD
Ex-dividend date
2026-ж., 30-окт.
P/E ratio
13,72
52-wk high
132,49 USD
52-wk low
68,77 USD
EPS
5,89 USD
Beta
0,67
Shares outstanding
406,32 млн
No. of employees
14 миң
Open
84,84 USD
High
85,13 USD
Low
80,71 USD
Mkt. cap
32,83 млд
Avg. vol.
4,46 млн
Volume
4,71 млн
Dividend
2,62%
Quarterly dividend
0,53 USD
Ex-dividend date
2026-ж., 30-окт.
P/E ratio
13,72
52-wk high
132,49 USD
52-wk low
68,77 USD
EPS
5,89 USD
Beta
0,67
Shares outstanding
406,32 млн
No. of employees
14 миң
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14,5 миң
Founded1952
HeadquartersParsippany-Troy Hills, Нью Джерси, Америка Кошмо Штаттары
SectorHealth Care
IndustryPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
3
Hold
8
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current 80,79 USD
115,00 USD (+42,34%)
Average
87,00 USD (+7,69%)
Lowest
74,00 USD (-8,40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Hold
Maintained
85,00 USD
+5,2%
11/17/2026
David Westenberg
Piper Sandler
Hold
Maintained
80,00 USD
-1%
11/09/2026
Andrea Alfonso
UBS
Hold
Maintained
85,00 USD
+5,2%
11/06/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
11/06/2026
Jonathan Block
Stifel Nicolaus
Hold
Maintained
85,00 USD
+5,2%
11/05/2026
Erin Wright
Morgan Stanley
Buy
Maintained
82,00 USD
+1,5%
10/30/2026
Keith Devas
Jefferies
Hold
Downgraded
83,00 USD
+2,7%
10/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
115,00 USD
+42,3%
10/16/2026
Matthew Dellatorre
Goldman Sachs
Hold
Initiated
74,00 USD
-8,4%
10/16/2026
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Steve Scala
TD Cowen
Buy
Reiterated
94,00 USD
+16,4%
08/25/2026
Daniel Grosslight
Citi
Buy
Maintained
96,00 USD
+18,8%
08/11/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
95,00 USD
+17,6%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
131,00 USD
+62,1%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
160,00 USD
+98%
02/26/2026
Last report
2026-ж., 5-ноя.
Fiscal period
Q3 2026
1,75 USD / 1,51 USD
+15,81%beat
Revenue / Est. (USD)
2,39 млд / 2,30 млд
+3,88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
2,39 млд
2,26 млд
2,47 млд
2,39 млд
Cost of goods sold
711,00 млн
640,00 млн
670,00 млн
696,00 млн
Cost of revenue
711,00 млн
640,00 млн
670,00 млн
696,00 млн
Research and development expenses
199,00 млн
180,00 млн
173,00 млн
174,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
618,00 млн
584,00 млн
589,00 млн
577,00 млн
Operating expense
848,00 млн
795,00 млн
793,00 млн
782,00 млн
Total operating expenses
1,56 млд
1,44 млд
1,46 млд
1,48 млд
Operating income
828,00 млн
827,00 млн
1,00 млд
913,00 млн
Other non operating income
-6,00 млн
-1,00 млн
-2,00 млн
-3,00 млн
EBT including unusual items
761,00 млн
758,00 млн
866,00 млн
729,00 млн
EBT excluding unusual items
780,00 млн
779,00 млн
948,00 млн
857,00 млн
Income tax expense
158,00 млн
157,00 млн
175,00 млн
138,00 млн
Effective tax rate
20,76%
20,71%
20,21%
18,93%
Other operating expenses
-
-
-
-
Net income
603,00 млн
601,00 млн
691,00 млн
591,00 млн
Net profit margin
25,26%
26,57%
28,00%
24,72%
Earnings per share
1,48
1,53
1,87
1,75
Interest and investment income
25,00 млн
21,00 млн
16,00 млн
17,00 млн
Interest expense
-57,00 млн
-62,00 млн
-61,00 млн
-62,00 млн
Net interest expenses
-32,00 млн
-41,00 млн
-45,00 млн
-45,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
903,00 млн
946,00 млн
1,12 млд
1,03 млд
Gain or loss from assets sale
-
-6,00 млн
-1,00 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору